Farmas USA

Hola 4reales.

Respondiendo a tu pregunta, de NVAX llevo calls strike 4 Jul13 que me costaron 0,8 cada uno en su día. El viernes se cerró la última transacción a 0,9.

Mucho ojo, que la liquidez y las horquillas son de pesadilla, ¿eh?

Saludos.

Solrac.

Posiblemente sea el único chalao del foro que lleve Aria, pero ahí lo dejo por si a alguien le interesa:

Jefferies Upgrades ARIAD Pharmaceuticals (ARIA) to Buy Following Hematologists/Oncologists Survey on Iclusig

http://www.streetinsider.com/Analyst+Comments/Jefferies+Upgrades+ARIAD+Pharmaceuticals+%28ARIA%29+to+Buy+Following+HematologistsOncologists+Survey+on+Iclusig/9442299.html

ARIA.

NVAX

Y no nos pone a parir??
Ummmm ... Que sensacion mas inusual ....

Aquí estamos chalados todos, sino no estaríamos aquí.

Le ha faltado tiempo :

"$NNVC has a MERS vaccine candidate ready for animal testing. Problem solved, no doubt."

El Bastardo

edito: 100 millones de market cap. CHICHARRIN!

En eso llevas toda la razón! jeje

Pues nada, cada loco con su tema y todos felices.

Más competencia: HEB saca comunicado de que su Alferon es eficaz frente al MERS, pero in vitro :)

Alferon® N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

……Non-Human Primate Animal Testing Planned as This Deadly New Virus Now Reaches The United States and Southeast Asia, and Disease Incidence Accelerates

PHILADELPHIA, PA, May 5, 2014 - Hemispherx Biopharma (NYSE MKT: HEB) announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication of the MERS virus in vitro. MERS-CoV is a recently emerged human coronavirus responsible for the lethal pulmonary syndrome known as MERS (Middle East Respiratory Syndrome). Recent testing in laboratories of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has revealed that Alferon® N was inhibitory to MERS-CoV both when used before test cells were exposed to MERS-CoV, as well as after the cells were exposed to the deadly virus.

Over 400 cases of MERS infection, including over 100 deaths, have been reported to date. More than 200 new cases of MERS infection were seen in the month of April, exceeding the total for the preceding two years since the disease emerged in 2012, according to the Center for Infectious Disease Research and Policy (CIDRAP) on April 30, 2014. Health officials say there is no known cure for MERS, and they have little information about the origins of the virus and how it is transmitted.

NIAID researchers led the Alferon® N MERS-CoV experiments. They treated monkey kidney cells with Alferon® N either 18 hours prior to infection with MERS-CoV ("pre-treatment”) or 1 hour following infection with MERS-CoV ("post-treatment”). At Day 1 and Day 3, supernatants were collected from cells and virus titers were thereafter measured. In both cases, Alferon® N showed significant dose-dependent inhibitory effects, thus suggesting the potential of Alferon® N both as a preventive and a potential treatment. Laboratory (in vitro) studies of potential antiviral agents are not necessarily predictive of clinical benefits. The Company was not involved in the conduct of the experimentation. The results were forwarded to Hemispherx at the conclusion of the experiments and formal publication is pending.

Juergen Richt, DVM, PhD, Regents Distinguished Professor at Kansas State University, stated "This is encouraging news. Non-human primate animal model testing of Alferon may give us more definitive data about the efficacy of this natural interferon against MERS.”

The deadly MERS disease, originally identified in the Middle East, has recently claimed its first victims in Southeast Asia killing a Malaysian man who returned from pilgrimage in Saudi Arabia according to WHO as reported in the WSJ on April 18, 2014. Although this did not happen during the past hajj, infectious disease specialists have been concerned that the illness could spread far afield by the millions of pilgrims who come to the Saudi holy city of Mecca each year for the Muslim pilgrimage. Most of the identified cases have been in Saudi Arabia although increasing numbers are being reported in the Gulf countries. Europe has reported a handful of cases, all with links to the Middle East. The US has just reported its first case of MERS. MERS has been estimated to kill about ¼ (one-fourth) of the people it infects, largely through respiratory infections. The MERS-CoV replicates in camels which may serve as an animal reservoir for the virus. About half of the current cases have involved health workers. Alferon® N has been demonstrated previously to be active against SARS-CoV (Emerging Infectious Disease, Vol. 10, No. 4, April 2004), a closely related human coronavirus responsible for the deadly SARS (Severe Acute Respiratory Syndrome) pandemic. The SARS pandemic that was contained nevertheless resulted in global concern and economic challenges for China, Malaysia, and Canada (http://www.cbc.ca/news/health/mers-virus-outbreak-raising-sars-like-concern-1.2615531).

Hemispherx now plans to expand a comprehensive testing program in collaboration with government researchers.